Evoke Pharma, Inc.

EVOK

US30049G2030

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:30:01 2024-04-26 pm EDT			5-day change	1st Jan Change
0.458 ^USD	+5.05%		-2.24%	-56.39%

Apr. 24	Transcript : Evoke Pharma, Inc. - Special Call
Mar. 21	Evoke Pharma, Inc. Announces Board Changes as of March 31, 2024	CI

Evoke Pharma, Inc. Announces Board Changes as of March 31, 2024

March 21, 2024 at 04:15 pm EDT

Evoke Pharma, Inc. announced that Matthew J. D?Onofrio will assume Mr. Gonyer?s board seat as of March 31, 2024 upon Mr. Gonyer?s departure for personal reasons. Mr. D?Onofrio currently serves as President and Chief Operating Officer.

Latest news about Evoke Pharma, Inc.

Transcript : Evoke Pharma, Inc. - Special Call	Apr. 24
Evoke Pharma, Inc. Announces Board Changes as of March 31, 2024	Mar. 21	CI
Evoke Pharma, Inc. Announces Chief Executive Officer Changes as of March 31, 2024	Mar. 21	CI
Transcript : Evoke Pharma, Inc., Q4 2023 Earnings Call, Mar 14, 2024	Mar. 14
Evoke Pharma, Inc. Provides Earnings Guidance for 2024	Mar. 14	CI
Evoke Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
Evoke Pharma Prices Underwritten Public Offering	Feb. 09	MT
Evoke Pharma Says FDA Lists Latest US Patent for Gimoti in Orange Book	Nov. 27	MT
Evoke Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Evoke Pharma, Inc. Provides Summary of Real-World Data on the Positive Impact of GIMOTI	Nov. 01	CI
Evoke Pharma, Inc. Enters into Sixth Amendment to Lease with SB Corporate Centre III-IV, LLC	23-10-12	CI
Evoke Pharma, Inc. Receives Notice of Allowance from U.S. Patent and Trademark Office for GIMOTI	23-09-14	CI
Evoke Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Transcript : Evoke Pharma, Inc. - Special Call	23-06-22
North American Morning Briefing : Retail Sales, -2-	23-05-16	DJ
Evoke Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Evoke Pharma Patent Added To US FDA Orange Book Of Drug Products	23-05-01	MT
Evoke Pharma, Inc. Announces United States Patent and Trademark Office Issues US Patent No. 11,628,150 Under the Title Nasal Formulations of Metoclopramide	23-04-20	CI
Evoke Pharma Says US Patent and Trademark Office Grants Formulation Patent Covering GIMOTI Nasal Spray	23-04-20	MT
Evoke Pharma's Q4 Loss per Share Narrows, Revenue Gains	23-03-21	MT
Evoke Pharma, Inc. Provides Revenue Guidance for 2023	23-03-21	CI
Transcript : Evoke Pharma, Inc., Q4 2022 Earnings Call, Mar 21, 2023	23-03-21
Earnings Flash (EVOK) EVOKE PHARMA Posts Q4 Revenue $796,000	23-03-21	MT
North American Morning Briefing : Stock Futures -2-	23-03-21	DJ
Evoke Pharma, Inc. Auditor Raises 'Going Concern' Doubt	23-03-20	CI

Chart Evoke Pharma, Inc.

Duration

Period

More charts

Company Profile

Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of drugs to treat gastrointestinal (GI) disorders and diseases. The Company operates through the development and commercialization of pharmaceutical products. It is developing its product, Gimoti (metoclopramide) nasal spray, the first and only nasally administered product indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. It developed Gimoti, a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with pro-motility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti is a novel formulation of metoclopramide offering systemic delivery by nasal spray administration. It has developed the nasal formulation of metoclopramide to provide its targeted patient population with acute or recurrent symptoms of diabetic gastroparesis.

Sector

Pharmaceuticals

Calendar

2024-05-13 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Evoke Pharma, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.458 USD

Average target price

7 USD

Spread / Average Target

+1,428.38%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
EVOKE PHARMA, INC.	-56.39%	3.88M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals

Evoke Pharma, Inc.

Equities

EVOK

US30049G2030

Pharmaceuticals

Evoke Pharma, Inc. Announces Board Changes as of March 31, 2024

EPS Revisions